Beyond GLP-1:
Can triple agonists
move the needle?

The revolution in pharmaceutical weight management has already happened. What comes next is scientifically more interesting: can a drug influence not just how much we want to eat, but how the body allocates, spends and defends its energy stores?

For decades, durable double-digit weight reduction was difficult to achieve with medication. Semaglutide established a new standard; tirzepatide exceeded it in a direct trial; and Eli Lilly’s investigational retatrutide has now produced approximately 25% average weight loss in a pivotal Phase 3 trial. Yet the progression from one receptor to three is not a simple arithmetic exercise. Human metabolism is a network of interacting feedback loops, and adding a hormonal signal changes the behavior of that entire network.

1. GLP-1: A hormone that connects the gut, pancreas and brain

Glucagon-like peptide-1 (GLP-1) is an incretin released primarily by intestinal L cells after nutrients enter the gastrointestinal tract. Incretins help explain why swallowed glucose stimulates more insulin release than an equivalent intravenous glucose exposure: the gut is telling the pancreas that incoming fuel must be handled.

The GLP-1 receptor belongs to the G-protein-coupled receptor (GPCR) family. Its activation commonly engages the stimulatory G-protein and raises intracellular cyclic AMP (cAMP), which influences signaling pathways including protein kinase A and EPAC. In pancreatic beta cells, this amplifies insulin secretion when glucose is elevated. GLP-1 also inhibits inappropriate glucagon secretion during hyperglycemia. Its glucose dependence is one reason GLP-1 agonists alone generally cause less hypoglycemia than agents that stimulate insulin regardless of glucose concentration.

Yet its anti-obesity impact is not simply pancreatic. GLP-1-responsive neural circuits in the brainstem and their connections to hypothalamic and other feeding networks influence hunger, meal size, satiety and food reward. Gastric emptying can also be slowed, especially early in treatment. Those effects are related, but not synonymous: feeling full after a small meal is different from experiencing less desire to begin another meal.

Natural GLP-1 lasts only minutes because it is rapidly degraded by DPP-4. Semaglutide is engineered for resistance to degradation and extended albumin binding, allowing prolonged receptor engagement with once-weekly injection. That converts a brief endogenous signal into sustained pharmacological pressure on appetite and glucose-regulatory circuits.

In STEP 1, injectable semaglutide 2.4 mg produced 14.9% average weight reduction at 68 weeks, versus 2.4% with placebo. That result established a striking therapeutic benchmark—but it did not suspend the body’s normal adaptations to losing mass.

2. Tirzepatide: Why GIP changes the equation

Glucose-dependent insulinotropic polypeptide (GIP) is another incretin, produced primarily by intestinal K cells. Like GLP-1, it potentiates glucose-dependent insulin secretion. But GIP signaling also affects adipose tissue, pancreatic alpha cells and central neural pathways. Those effects change with metabolic context: the same receptor can participate in different physiological responses depending on nutrient availability, insulin sensitivity, interacting hormones and tissue-specific signaling.

There is a genuine scientific paradox here. GIP has historically been associated with nutrient handling and fat storage, so why should activating its receptor help people lose more weight? The answer is not fully settled. Chronic pharmacological agonism combined with GLP-1 activity need not mimic short-lived GIP signals in isolation. The added effect may involve interacting appetite pathways, changes in receptor signaling and altered tolerance of effective GLP-1 exposure. Intriguingly, researchers are also investigating GIP antagonism in combination with GLP-1 activation. This is not proof that the pathways are equivalent; it is evidence that our simplified descriptions of GIP biology are incomplete.

In the randomized SURMOUNT-5 comparison, tirzepatide produced 20.2% average weight reduction versus 13.7% for semaglutide at 72 weeks in adults with obesity without diabetes. That 6.5-percentage-point advantage is direct clinical evidence. We should distinguish it from the still-evolving question of precisely why the GIP component contributes to superior efficacy.

3. Retatrutide: Why add a hormone that raises blood glucose?

Retatrutide is a single engineered peptide activating GLP-1, GIP and glucagon receptors. The first two pathways extend the incretin strategy. The third is an apparent contradiction: glucagon, secreted from pancreatic alpha cells, is classically insulin’s counterregulatory partner. During fasting or hypoglycemia, glucagon encourages the liver to release glucose by breaking down glycogen and producing new glucose.

Why deliberately stimulate that system in people with obesity, some of whom have impaired glucose regulation? Because glucagon is more than a glucose-raising switch. It also affects hepatic lipid and amino-acid metabolism, mobilization of energy substrates and, under some conditions, energy expenditure. Experimental work implicates pathways including FGF21 and changes in lipid oxidation. The idea is to combine the appetite- and glucose-related actions of GLP-1/GIP with glucagon’s potential catabolic contribution, while the incretin components help counterbalance glucagon’s tendency to raise glucose.

At the receptor level, all three targets are GPCRs that can signal through cAMP, but shared second messengers do not imply interchangeable effects. Their anatomical expression, receptor potency, signaling bias, ligand exposure and the patient’s prevailing metabolic state all matter. A cAMP signal in a pancreatic beta cell is not the same biological event as cAMP signaling in a hepatocyte or neuron.

Clinical results are compelling. The Phase 2 high-dose group lost 24.2% on average at 48 weeks. In the 2,339-participant Phase 3 TRIUMPH-1 trial, the treatment-regimen analysis at 80 weeks showed 17.6% loss with 4 mg, 23.7% with 9 mg and 25.0% with 12 mg, compared with 3.9% for placebo. These are strong placebo-controlled results—not a head-to-head demonstration of superiority to obesity-dose tirzepatide.

4. Homeostasis: The body is not a passive recipient

A patient’s energy requirements change as their weight falls. Smaller bodies generally expend less energy; circulating leptin falls with fat loss; hunger and other counterregulatory signals may increase. In some circumstances adaptive changes in energy expenditure go beyond those predicted by body mass alone. The body continually integrates its internal state with food availability, activity, sleep, stress and prior weight history.

Consider two people who each weigh 290 pounds. One has substantial skeletal muscle, greater physical activity and relatively preserved insulin sensitivity. The other has less lean mass, greater insulin resistance and repeated cycles of weight loss and regain. Their scale readings match. Their baseline metabolism, physiological reserves and responses to the same receptor agonist may not.

This is why percentage weight loss is informative but incomplete. Drug dose, receptor activation, body composition, adherence, individual response and compensatory feedback interact over months and years. Pharmacology changes inputs; physiology determines the evolving response. A plateau may reflect a new energy equilibrium, not necessarily a drug that has stopped working.

5. What do patients gain—and what do they give up?

More weight loss is not automatically better for every patient. Losing 25% of body weight may be enormously valuable for severe obesity, but a person with substantial muscle mass and a more modest target may prioritize functional strength, tolerability and maintenance. Loss of fat-free mass should not automatically be equated with loss of contractile muscle; nevertheless, strength and physical function deserve measurement alongside the scale.

In TRIUMPH-1, nausea affected approximately 42% and vomiting approximately 25% of participants receiving 12 mg retatrutide; about 11% discontinued because of adverse events. Another finding deserves explicit attention: dysesthesia, an altered or uncomfortable skin sensation that may be described as tingling, burning or sensitivity to touch, was reported in 12.5% at 12 mg versus 0.9% with placebo. It is not necessarily unique to retatrutide or a proven glucagon-specific effect. Most reported cases in the trial were mild or moderate and many resolved during treatment, but incidence, persistence and patient tolerance deserve scrutiny. Earlier retatrutide studies also observed dose-associated heart-rate increases. Those findings demand careful long-term evaluation, not dismissal simply because efficacy is impressive.

6. Amylin: Not a fourth rung, but another ladder

Amylin is a peptide co-secreted with insulin by pancreatic beta cells. It helps regulate meal termination, delays gastric emptying and suppresses post-meal glucagon secretion. Its receptors involve the calcitonin receptor paired with receptor activity-modifying proteins (RAMPs), an architecture distinct from the GLP-1/GIP/glucagon receptor family.

Amylin signaling acts prominently through the area postrema and connected brainstem circuits, influencing the size of meals and the sensation that it is time to stop eating. That makes it an appealing complement to GLP-1: it is not simply more GLP-1 receptor stimulation.

Novo Nordisk combined the long-acting amylin analogue cagrilintide with semaglutide in CagriSema. In REDEFINE 1, the combination produced 20.4% average weight reduction versus 3.0% with placebo at 68 weeks. But a later direct comparison in REDEFINE 4 produced 20.2% weight loss with CagriSema versus 23.6% with tirzepatide at 84 weeks under the treatment-regimen analysis, and failed its noninferiority objective.

That result does not invalidate amylin. It illustrates that a credible biological mechanism and meaningful weight reduction do not automatically create the most competitive therapy. Dose, receptor balance, tolerability, treatment duration and the chosen comparator determine the practical value. Newer single-molecule GLP-1/amylin approaches—including investigational zenagamtide, previously called amycretin—extend this alternative branch of metabolic pharmacology.

7. Where the next real advances may come from

The relevant endpoints will broaden beyond maximum mean weight loss: durability over years, preservation of lean tissue and physical function, cardiovascular and renal outcomes, liver disease, sleep apnea, tolerability, adherence and affordability. There may ultimately be room for several therapeutic profiles rather than a single winner.

Crucially, clinical trial percentages must be read honestly. Semaglutide STEP 1 ran 68 weeks; tirzepatide and semaglutide were compared directly over 72 weeks in SURMOUNT-5; retatrutide’s TRIUMPH-1 ran 80 weeks. Different populations, durations and statistical estimands limit naive rankings. The direct comparison establishes tirzepatide’s advantage over semaglutide in the studied population; retatrutide’s apparent next step still requires appropriate head-to-head interpretation.

← Back to Therapeutics